GEN Exclusives

More »

GEN News Highlights

More »
Apr 6, 2009

Mitsubishi Tanabe Signs On Affectis for Discovery Work for Antidepressants

  • Mitsubishi Tanabe Pharma (MTPC) will use Affectis Pharmaceuticals’ behavioral pharmacology expertise and technology in its drug discovery efforts. Affectis will receive research fees and is eligible to developmental milestones. 
     
    MTPC’s ongoing drug discovery program is reportedly based on a novel depression target that Affectis helped validate in a previous collaboration. The deal, which was inked in February 2005, covered the use of Affectis’ Behavioural Interference™ platform.

    Under the new agreement, MTPC will continue to utilize this technology and Affectis’ expertise. Affectis has two antidepressant discovery programs and one Phase II candidate for depression.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »